NAVIDEA BIOPHARMACEUTICALS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch NAVBQ and buy or sell other stocks, ETFs, and their options commission-free!

About NAVBQ

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. 

CEO
Michael S. Rosol, PhD
CEOMichael S. Rosol, PhD
Employees
15
Employees15
Headquarters
Columbus, Ohio
HeadquartersColumbus, Ohio
Founded
1983
Founded1983
Employees
15
Employees15

NAVBQ Key Statistics

Market cap
10.01K
Market cap10.01K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
8.10K
Average volume8.10K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.05
52 Week high$0.05
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

NAVIDEA BIOPHARMACEUTICALS INC(NAVBQ) stock is priced at $0.00, giving the company a market capitalization of 10.01K.

During the trading day, NAVIDEA BIOPHARMACEUTICALS INC(NAVBQ) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 8.1K.

The stock's 52-week range extends from a low of $0.00 to a high of $0.05.

The stock's 52-week range extends from a low of $0.00 to a high of $0.05.

People also own

Based on the portfolios of people who own NAVBQ. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.